Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The randomized double-blind reminder study

Gilles Montalescot, Bertram Pitt, Esteban Lopez de Sa, Christian W. Hamm, Marcus Flather, Freek Verheugt, Harry Shi, Eva Turgonyi, Miguel Orri, John Vincent, Faiez Zannad, Georg Noll, Robin Weir, Blair O'Neill, Michael Böhm, W. Stuart Hillis, Andrew Grieve, Jean-Lucien Rouleau, Filippatos Gerasimos, David FitchettSerge Lepage, Minakshi Madan, Bruce Sussex, Gerald Tremblay, Robert Welsh, Graham Wong, Martin Hutyra, Jiri Kettner, Petr Ostadal, Jindrich Spinar, Jan Vojacek, Michel Barboteu, Jean-Philippe Collet, Pierre Coste, Yves Cottin, Dominique Ducos, Michel Galinier, Emmanuel Teiger, Gilles Zemour, Johann Bauersachs, Rainer Hambrecht, Gerhard Hauf, Hubertus Heuer, Harald Mudra, Thomas Munzel, Stephan Steiner, Ruth Strasser, Karsten Sydow, Carsten Tschope, Rolf Wachter, Nikos Werner, Dimitros Alexopoulos, Dimitrios Babalis, Vlassios Pyrgakis, Csaba Dezsi, Geza Lupkovics, Peter Polgar, Janos Tomcsanyi, J. Herrman, J. M. ten Berg, Jerzy Gorny, Jacek Kubica, Jerzy Lewczuk, Witold Zmuda, Marian Hranai, Frantisek Kovar, Roman Margoczy, Karol Micko, Jaroslav Sumbal, Xavier Bosch Genover, Antonio Fernandez Ortiz, Migue Fiol Sala, Cosme Garcia Garcia, Carlos Perez Munoz, Juan Ramon Rey Blas, Franciso Ridocci Soriano, Dawn Adamson, Farqad Alamgir, Anoop Chauhan, Gregory Lip, Thomas Martin, Gerry McCann, David Newby, David Smith

Research output: Contribution to journalArticlepeer-review

129 Citations (Scopus)


Aims: We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset. Methods and results: In this randomized, placebo-controlled, double-blind trial, we assigned 1012 patients with acute STEMI and without a history of heart failure to receive either eplerenone (25–50 mg once daily) or placebo in addition to standard therapy. The primary endpoint was the composite of CV mortality, re-hospitalization, or, extended initial hospital stay, due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40%, or elevated BNP/NT-proBNP at 1 month or more after randomization. BNP elevation was defined as BNP levels or values above 200 pg/mL or NT-proBNP values above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50–75 years) or above 1800 pg/mL (patients older than 75). After a mean follow-up of 10.5 months, the primary endpoint occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the placebo group [adjusted hazard ratio (HR), 0.58; 95% confidence interval (CI), 0.45–0.76; P < 0.0001]. The primary endpoint was driven by a high BNP/NT-proBNP level (adjusted HR, 0.60; 95% CI, 0.45–0.79; P < 0.0003). Adverse event rates were similar in both groups. Serum potassium levels exceeded 5.5 mmol/L in 5.6 vs. 3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 vs. 5.6% of patients (P = 0.0002), in the eplerenone and placebo groups, respectively. Conclusion: The addition of eplerenone during the acute phase of STEMI was safe and well tolerated. It reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels. Additional studies are needed to clarify the role of early use of MRAs in STEMI patients without heart failure.
Original languageEnglish
Pages (from-to)2295-2302
Number of pages8
JournalEuropean Heart Journal
Issue number34
Early online date29 Apr 2014
Publication statusPublished - 7 Sep 2014


  • Myocardial infarction
  • Mineralocorticoid receptor antagonists
  • Eplerenone
  • B-type natriuretic peptide
  • Potassium

Cite this